Servier, an independent international pharmaceutical group governed by a foundation, announced that it has entered into a definitive agreement to acquire Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on developing targeted therapies for life-threatening diseases. The transaction values Day One at approximately $2.5 billion.
Under the terms of the agreement, Servier will acquire Day One for $21.50 per share in cash. The offer represents a premium of about 68% over Day One’s closing share price on March 5, 2026, and approximately an 86% premium over the company’s one-month volume weighted average price as of the same date.
The acquisition is intended to strengthen Servier’s position in oncology targeted therapies and expand its rare oncology portfolio. The combined capabilities of Servier and Day One are expected to accelerate the development of treatments for patients with cancers that have high unmet medical needs.
Servier plans to fund the transaction using existing cash and investments. The deal will be executed through a tender offer to acquire all issued and outstanding shares of Day One’s common stock. Following completion of the tender offer, any remaining shares will be acquired through a second-step merger at the same per-share price.
The transaction remains subject to customary closing conditions, including regulatory approvals and the tender of a majority of Day One’s outstanding shares. The companies expect the deal to close in the second quarter of 2026.
Advisors on the transaction include Goldman Sachs Bank Europe SE, which is serving as exclusive financial advisor to Servier, with Baker McKenzie acting as legal counsel. Centerview Partners LLC is serving as exclusive financial advisor to Day One, and Fenwick & West LLP is acting as legal counsel.
KEY QUOTES:
“This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier’s position in rare oncology. It reflects our long-term commitment to investing in science that can make a meaningful difference for patients. This announcement is fully aligned with our 2030 ambition, and we believe that combining our expertise will accelerate innovation for people living with a rare cancer.”
Olivier Laureau, President of Servier
“Servier’s successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One’s mission to bring medicines to patients of all ages with life threatening diseases. Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low-grade glioma. Importantly, Servier’s dedication to the rare disease community preserves the patient-first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve.”
Jeremy Bender, Ph.D., Chief Executive Officer of Day One Biopharmaceuticals
